FRUZAQLA® (fruquintinib) safety profile

In FRESCO and FRESCO-2 clinical trials, adverse reactions were manageable and predictable* with FRUZAQLA1-4

In pooled monotherapy studies, among the 911 patients who received FRUZAQLA, 23% were exposed for 6 months or longer and 3.5% were exposed for greater than one year.1 These patients received at least one dose of FRUZAQLA at the recommended dosage of 5 mg daily for the first 21 days of each 28-day cycle.1

The most common adverse reactions (incidence ≥20%) following treatment with FRUZAQLA in pooled monotherapy studies included1:

  • hypertension
  • palmar-plantar erythrodysesthesia (hand-foot skin reactions)
  • proteinuria
  • dysphonia
  • abdominal pain
  • diarrhea
  • asthenia

*Predictable refers to ARs consistent with inhibition of VEGF and VEGFR. 
Despite predictability, individual patient experiences may vary.

FRESCO-2 Safety Profile

FRESCO-2 was a global, double-blind, placebo-controlled study that evaluated the efficacy and safety of FRUZAQLA.

FRESCO Safety Profile

FRESCO was a single-country study that evaluated the efficacy and safety of FRUZAQLA.